Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
Public Deposited- Creator
-
Rudek, Michelle A.
- Other Affiliation: The Sidney Kimmel Comprehensive Cancer Center
-
Connolly, Roisin M.
- Other Affiliation: The Sidney Kimmel Comprehensive Cancer Center
-
Hoskins, Janelle M.
- University of North Carolina at Chapel Hill
- Other Affiliation: Gentris Corporation
-
Garrett-Mayer, Elizabeth
- Other Affiliation: Medical University of South Carolina
-
Jeter, Stacie C.
- Other Affiliation: The Sidney Kimmel Comprehensive Cancer Center
-
Armstrong, Deborah K.
- Other Affiliation: The Sidney Kimmel Comprehensive Cancer Center
-
Fetting, John H.
- Other Affiliation: The Sidney Kimmel Comprehensive Cancer Center
-
Stearns, Vered
- Other Affiliation: The Sidney Kimmel Comprehensive Cancer Center
-
Wright, Laurie A.
- Other Affiliation: The Sidney Kimmel Comprehensive Cancer Center
-
Zhao, Ming
- Other Affiliation: The Sidney Kimmel Comprehensive Cancer Center
-
Watkins Jr., Stanley P.
- Other Affiliation: Anne Arundel Medical Center
-
McLeod, Howard L.
- University of North Carolina at Chapel Hill
-
Davidson, Nancy E.
- Other Affiliation: UPMC Hillman Cancer Center
-
Wolff, Antonio C.
- Other Affiliation: The Sidney Kimmel Comprehensive Cancer Center
-
Rudek, Michelle A.
- Abstract
- The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer. However, toxicity and large interpatient pharmacokinetic variability occur despite body surface area (BSA)-dosing. We hypothesized that a fixed-dose schedule would simplify dosing and provide an effective and safe alternative to BSA-based dosing.
- Date of publication
- 2013
- Keyword
- Combinaison à dose fixe
- Capécitabine
- Cancer du sein
- Pharmacocinétique
- Cancer
- Anticancéreux
- Antipyrimidique
- Pyrimidine nucleoside
- Malignant tumor
- Pharmacokinetics
- Prodrug
- Stade avancé
- Mammary gland diseases
- Breast cancer
- Pharmacogenetics
- Promédicament
- Advanced stage
- Pharmacogénétique
- Breast disease
- Metastasis
- Capecitabine
- Genetics
- Fluoropyrimidine derivatives
- Antineoplastic agent
- Métastase
- DOI
- Identifier
- PMID: 23588952
- Onescience id: fe8fec6117dfcfd0367178d81dda03e931c351b5
- PMCID: PMC3673300
- Publisher DOI: https://doi.org/10.1007/s10549-013-2516-z
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- Breast Cancer Research and Treatment
- Journal volume
- 139
- Journal issue
- 1
- Page start
- 135
- Page end
- 143
- Language
- English
- ISSN
- 1573-7217
- 0167-6806
Relations
- Parents:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
EuropePMC-PMC3673300.pdf | October 30, 2020 | Public | Download |